Document:

EXECUTION VERSION

 

ROYALTY AGREEMENT

 

This ROYALTY AGREEMENT, dated as of August
24, 2012 (as amended, supplemented or otherwise modified from time to time, this “Royalty Agreement”), is made
by and between ROS Acquisition Offshore LP, a Cayman Islands Exempted Limited Partnership (together with its Affiliates, successors,
transferees and assignees, “ROS”), and Bacterin International, Inc., a Nevada corporation (“Bacterin”).
ROS and Bacterin are sometimes referred to herein individually as a “Party” and collectively as the “Parties;”.

 

WITNESSETH :

 

WHEREAS, ROS and Bacterin have entered into
that certain Credit Agreement, dated as of the date hereof (as subsequently amended or otherwise modified, the “Credit
Agreement”); and

 

WHEREAS, the execution and delivery of this
Royalty Agreement is a condition precedent to the making of the Initial Loan pursuant to the Credit Agreement.

 

NOW, THEREFORE, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, and in order to induce ROS to make the Loans pursuant to the Credit
Agreement, the Parties hereto agree as follows.

 

Article
I.

DEFINITIONS

 

Section
1.1           Certain Terms. The following terms (whether
or not underscored) when used in this Royalty Agreement, including its preamble and recitals, shall have the following meanings
(such definitions to be equally applicable to the singular and plural forms thereof):

 

“Applicable Amount” has
the meaning set forth in the definition of “Purchase Price”.

 

“Applicable Period” has
the meaning set forth in the definition of “Purchase Price”.

 

“Bacterin” has the meaning
set forth in the preamble hereto.

 

“Buy-Out Notice” has
the meaning set forth in Section 2.6.

 

“Buy-Out Option” has
the meaning set forth in Section 2.6.

 

“Confidential Information”
means any and all information or material (whether written or oral, or in electronic or other form) that, at any time before, on
or after the Closing Date, has been or is provided or communicated to the Receiving Party by or on behalf of the Disclosing Party
pursuant to this Royalty Agreement or in connection with the transactions contemplated hereby or any discussions or negotiations
with respect thereto.

 

“Contract” means any
contract, license, indenture, instrument or agreement.

 

    	 

    	 

    

 

“Contract Counterparty”
means any party (other than Bacterin or any of its Affiliates) to any Related Agreement.

 

“Credit Agreement” has
the meaning set forth in the recitals hereto.

 

“Default Rate” means
the rate of interest applicable to Loans under Section 3.5 of the Credit Agreement.

 

“Disclosing Party” means
the Party disclosing Confidential Information.

 

“Judgment” means any
judgment, injunction, order or decree.

 

“Law” means any law,
statute, rule, regulation or ordinance of any Governmental Authority that may be in effect from time to time.

 

“Net Sales” means, with
respect to each Product, the gross invoiced amount on sales of, and distribution income, stocking orders, transfer payments and
other consideration received in respect of, such Product in any Territory by Bacterin, any of its Affiliates, any Related Party
or any Sublicensee to or from, respectively, Third Parties after deduction of: (i) normal and customary trade, quantity or prompt
settlement discounts (including chargebacks, shelf stock adjustments and allowances) with respect to customers actually allowed;
(ii) amounts repaid or credited by reason of rejection, returns or recalls of goods, rebates or bona fide price reductions; (iii)
rebates and similar payments actually made with respect to sales paid for by Federal or state Medicaid, Medicare or similar programs
in the Territory; and (iv) excise taxes, customs duties, customs levies and import fees imposed on the sale, importation, use or
distribution of such Product (to the extent included in the gross invoiced amount), in each case as calculated (x) in a manner
consistent with Bacterin’s customary practice for its products and (y) consistent with GAAP. Net Sales with respect to sales
of such Product that are not made on an arm’s length basis or that are made for consideration other than cash shall be calculated
based on the average per-unit Net Sales of such Product during the applicable period without regard to such non-arm’s length
or non-cash sales.

 

“Party” and “Parties”
have the meanings set forth in the preamble hereto.

 

“Payments” means the
Royalty Payments, the payment of the Purchase Price and any other payments to be made by Bacterin to ROS hereunder.

 

“Purchase Price”
has the meaning set forth on Schedule 1.1 hereto.

 

    	- 2 -

    	 

    

 

“Put Notice” has the
meaning set forth in Section 5.2.

 

“Put Option” has the
meaning set forth in Section 5.2.

 

“Receiving Party” means
the Party receiving Confidential Information.

 

“Recipients” has the
meaning set forth in Section 7.1.

 

“Recovered Amount” means,
as of the time the Purchase Price is paid pursuant to Section 2.6 hereof, the aggregate amount of (i) all Royalty Payments
previously paid to ROS by Bacterin pursuant to Section 2.1 as of the Fiscal Quarter last ended, and (ii) all principal payments
made on the Loans, together with all interest accrued and paid thereon, as of the date the Purchase Price is paid (including payments
made on such date).

 

    	- 3 -

    	 

    

 

“Related Agreement” means
any existing or future Contract entered into before or during the Royalty Term by Bacterin or any of its Affiliates (i) relating,
directly or indirectly, to any Product or any Intellectual Property or (ii) that could reasonably be expected to affect, directly
or indirectly, the value of the Royalty Payments.

 

“Related Party” means
any Affiliate of Bacterin.

 

“Royalty Agreement” has
the meaning set forth in the preamble hereto.

 

“Royalty Event of Default”
has the meaning set forth in Section 5.1.

 

“ROS” has the meaning
set forth in the preamble hereto.

 

“Royalty Payment” has
the meaning set forth in Section 2.1(b).

 

“Royalty Report” has
the meaning set forth in Section 2.1(c).

 

“Royalty Term” means
the period commencing on the Closing Date and ending on the earlier of (i) the tenth anniversary of the Closing Date and (ii) the
date of payment of the Purchase Price pursuant to the exercise of the Put Option by ROS or the exercise of the Buy-Out Option by
Bacterin, as the case may be.

 

“Sublicense Agreement”
has the meaning set forth in Section 2.5(a).

 

“Sublicensee” means any
party (other than Bacterin or any of its Affiliates) to any Sublicense Agreement.

 

“Term” has the meaning
set forth in Section 6.1.

 

“Territory” means all
of the countries and territories of the world.

 

“Third Party” means any
Person, other than Bacterin or any of its Affiliates.

 

Section
1.2           Credit Agreement Definitions. Unless otherwise
defined herein or the context otherwise requires, terms used in this Royalty Agreement, including its preamble and recitals, have
the meanings provided in the Credit Agreement. In the event that the Credit Agreement terminates (in accordance with its terms
or otherwise) prior to the expiration of the Term, terms used herein and defined in the Credit Agreement (as in effect immediately
prior to such termination) shall continue to be used herein without regard to such earlier termination of the Credit Agreement
(as if such agreement remained in full force and effect).

 

Article
II.

ROYALTY PROVISIONS

 

Section
2.1           Royalty Payments.

 

(a)          Bacterin
shall pay to ROS, in respect of each Fiscal Year (or portion of a Fiscal Year, in the case of the first Fiscal Year and last Fiscal
Year of the Royalty Term) during the Royalty Term, a royalty amount equal to the sum of (i) 1.75% of the aggregate Net Sales of
all Products during such Fiscal Year (or portion of a Fiscal Year, as the case may be) up to $45,000,000 of such Net Sales, plus
(ii) 1.0% of the aggregate Net Sales of all Products during such Fiscal Year (or portion of a Fiscal Year, as the case may be)
in excess of $45,000,000.

 

    	- 4 -

    	 

    

 

(b)          Amounts
payable pursuant to Section 2.1(a) shall be calculated quarterly as of the last day of each Fiscal Quarter during the Royalty
Term, and shall be payable by Bacterin to ROS within 45 days after the end of each such Fiscal Quarter, except that the payment
for the last Fiscal Quarter of each Fiscal Year shall be payable within 90 days after the end of such Fiscal Year (each such payment,
a “Royalty Payment”). The first Royalty Payment shall be determined based on Net Sales for the entire Fiscal
Quarter in which the Closing Date occurs, and the last Royalty Payment (other than in the case of the Royalty Term ending on the
date of payment of the Purchase Price pursuant to the exercise of the Put Option by ROS or the exercise of the Buy-Out Option by
Bacterin) shall be determined based on Net Sales for the entire Fiscal Quarter in which the last day of the Royalty Term occurs.
Royalty Payments shall first be determined in the currency of the country in which the corresponding Net Sales occurred and then
converted to its equivalent in U.S. Dollars. The rates of exchange for such payments shall be the average rate for U.S. Dollars,
as quoted by JPMorgan Chase in New York City, at the close of business on the last day of the Fiscal Quarter in which such Net
Sales occurred.

 

(c)          Together
with each Royalty Payment, Bacterin shall deliver a written report to ROS showing with respect to each Product (on a product-by-product,
country-by-country and seller-by-seller basis) (i) Net Sales for such Product in such country and by such seller for the applicable
Fiscal Quarter, including line items for any deductions to the gross invoiced amount made pursuant to the definition of Net Sales,
and (ii) the calculation (in reasonable detail) of the Royalty Payment owed (including any applicable exchange rates used) and
paid for such Fiscal Quarter (each, a “Royalty Report”). Each delivery of a Royalty Report hereunder shall also
be deemed to constitute a representation and warranty by Bacterin that such Royalty Report is true, correct and complete in all
material respects.

 

Section
2.2           General Provisions as to Payments. All amounts
payable to ROS under this Royalty Agreement (including the Payments) shall be (i) made without set-off or counterclaim of any kind
or nature whatsoever, (ii) made in U.S. Dollars and in immediately available funds and (iii) remitted by wire transfer to such
bank account as shall have been designated by ROS in writing from time to time. Any Payments or other amounts due to ROS under
this Royalty Agreement that are not made on or before the applicable due date shall bear interest, payable on demand (and compounded
monthly), for each day from (and including) the applicable due date to (but excluding) the date of the payment thereof, at a rate
per annum equal to the Default Rate.

 

Section
2.3           Taxes. The Parties hereby covenant and agree
that, with respect to any Non-Excluded Taxes payable on any Payments payable to ROS under this Royalty Agreement, Section 4.3
of the Credit Agreement shall apply and is hereby incorporated herein by reference as if set forth herein in its entirety; provided
that references in such Section 4.3 to the “Borrower” shall be deemed to mean Bacterin, references to the “Lender”
shall be deemed to mean ROS, and references to the Credit Agreement shall be deemed to mean this Royalty Agreement.

 

    	- 5 -

    	 

    

 

Section
2.4           Records and Audit. Bacterin shall keep and maintain
at its chief executive office in the United States complete and accurate records (on a seller-by-seller, product-by-product, country-by-country
basis) of all sales, Net Sales, and deductions to arrive at Net Sales until the latest of (i) five years after the period to which
such records relate, (ii) the expiration of the applicable tax statute of limitations, and (iii) such longer period as applicable
Law requires. ROS shall have the right once per Fiscal Quarter during the Royalty Term and for a period of one year thereafter,
at ROS’ expense (except as set forth below), to investigate and audit such records, upon reasonable notice, during regular
business hours (and may, if it so chooses, retain an independent accountant to conduct such investigation and audit). Bacterin
shall, and shall cause its Affiliates to, cooperate fully and completely with such investigation and audit (and the Persons conducting
such investigation and audit), and all results of any investigation and audit under this Section 2.4 (and any associated
underlying data and information) shall be made available to both Bacterin and ROS. If such investigation and audit reveals an underpayment,
Bacterin shall remit such underpayment to ROS no later than 30 days after the completion of such investigation and audit. If the
underpayment with respect to any Fiscal Quarter that is included as a part of such investigation and audit is equal to or greater
than five percent (5%) of the amount that was otherwise due under the terms and conditions of this Royalty Agreement with respect
to such Fiscal Quarter, Bacterin shall pay all of the costs incurred by ROS in connection with such investigation and audit. If
the audit reveals an overpayment, ROS shall remit such overpayment to Bacterin no later than 30 days after the completion of such
investigation and audit.

 

Section
2.5           Related Agreements; Sublicense Agreements; Access
to Records.

 

(a)          Bacterin
shall provide ROS, upon request, with true, correct and complete copies of (i) each Related Agreement (including all amendments
and supplements thereto) and (ii) each Contract (including all amendments and supplements thereto) (1)(x) relating, directly or
indirectly, to any Product or any Intellectual Property or (y) that could reasonably be expected to affect, directly or indirectly,
in any material respect the value of the Royalty Payments and (2) that involves rights relating to any Product or any Intellectual
Property that were originally obtained, directly or indirectly, from Bacterin (or any Affiliate of Bacterin) (a “Sublicense
Agreement”).

 

(b)          Bacterin
shall, shall cause its Affiliates to, and shall use commercially reasonable efforts to cause each Contract Counterparty and Sublicensee
to, (i) furnish ROS with any Related Agreement or Sublicense Agreement required to be furnished pursuant to Section 2.5(a),
(ii) keep and maintain at its respective chief executive office complete and accurate records (on a seller-by-seller, product-by-product
and country-by-country basis) of all sales, Net Sales, and deductions to arrive at Net Sales effected by such Person until the
latest of (x) five years after the period to which such records relate, (y) the expiration of the applicable tax statute of limitations
and (z) such longer period as applicable Law requires, and (iii) provide ROS with access to such records to verify and audit the
Net Sales attributable to Bacterin or such Affiliate, Related Party or Sublicensee in accordance with the audit and inspection
process described in Section 2.4.

 

    	- 6 -

    	 

    

 

Section
2.6           Buy-Out Option. At any time after the Closing
Date, Bacterin shall have the right, exercisable in its sole discretion (the “Buy-Out Option”), to purchase
from ROS all (but not less than all) of its rights to the remaining Royalty Payments that will become due pursuant to Section
2.1. The amount payable by Bacterin to ROS in respect of the Buy-Out Option shall be the Purchase Price. If Bacterin elects
to exercise its Buy-Out Option, it shall so notify ROS in writing (the “Buy-Out Notice”). Delivery of a Buy-Out
Notice (and exercise of the Buy-Out Option) shall be irrevocable. Upon receipt of a Buy-Out Notice, ROS shall promptly (and, in
any event, within three Business Days) advise Bacterin of the Purchase Price, which Purchase Price shall be conclusive absent manifest
error. Bacterin shall, on the fifth Business Day following ROS’ receipt of such Buy-Out Notice, (i) purchase from ROS all
(but not less than all) of its rights to the remaining Royalty Payments that will become due pursuant to Section 2.1, and
(ii) repay in full all outstanding principal of the Loans and all other monetary Obligations, together with all accrued but unpaid
interest and fees thereon or in respect thereof, if any. The payment of the Purchase Price shall be made by wire transfer of immediately
available funds to an account designated by ROS. Repayment of principal, interest or fees shall be made in accordance with the
applicable terms of the Credit Agreement. Any term or provision hereof to the contrary notwithstanding, Bacterin shall only have
the right to exercise the Buy-Out Option if, prior to or simultaneously with the payment of the Purchase Price, Bacterin shall
have repaid in full in cash the entire principal amount of the Loans, together with all accrued and unpaid interest thereon, and
all outstanding fees, expenses and other monetary Obligations, if any, payable under the Credit Agreement, this Royalty Agreement
or any other Loan Document.

 

Article
III.

REPRESENTATIONS AND WARRANTIES

 

Bacterin hereby represents and warrants
to ROS as of the Closing Date as follows:

 

Section
3.1           Credit Agreement Representations and Warranties.
The representations and warranties of the Borrower contained in Article VI of the Credit Agreement are true and correct in all
material respects, each such representation and warranty set forth in such Article and all other terms of the Credit Agreement
to which reference is made therein, together with all related definitions and ancillary provisions, being hereby incorporated into
this Royalty Agreement by this reference as though specifically set forth in this Article.

 

Section
3.2           Enforceability. Bacterin has the power
and authority and the legal right to enter into this Royalty Agreement and perform its obligations hereunder and has taken all
necessary action on its part required to authorize the execution and delivery of this Royalty Agreement and the performance of
its obligations hereunder. This Agreement has been duly executed and delivered on behalf of Bacterin, constitutes a legal, valid
and binding obligation of Bacterin and is enforceable against Bacterin in accordance with its terms (except as such enforceability
may be limited by applicable bankruptcy, insolvency, reorganization or similar Laws affecting creditors’ rights generally
and by principles of equity).

 

Section
3.3           Compliance with Laws and Related Agreements.
None of Holdings, Bacterin or any of the Subsidiaries is in violation in any material respect of, or under investigation with respect
to any material violation of, and none of Holdings, Bacterin or any of the Subsidiaries has been threatened to be charged with
the violation in any material respect of, or been given notice of any material violation of, any Law or Judgment applicable to
such Person. None of Holdings, Bacterin or any of the Subsidiaries has breached or defaulted under any provision of any Related
Agreement in any material respect, and, to the knowledge of Bacterin, no Contract Counterparty has breached or defaulted under
any provision of any Related Agreement in any material respect. To the knowledge of Bacterin, no event has occurred that, upon
notice or passage of time or both, could reasonably be expected to give rise to any material breach or termination of or default
under any Related Agreement by any party thereto.

 

    	- 7 -

    	 

    

 

Article
IV.

COVENANTS

 

Bacterin covenants and agrees with ROS that
throughout the Term Bacterin will, and will cause Holdings and each of the Subsidiaries to, perform or cause to be performed the
obligations set forth below.

 

Section
4.1           Credit Agreement Covenants. Bacterin covenants
and agrees that, throughout the Term, it will perform, comply with and be bound by all of the agreements, covenants and obligations
contained in Articles VII and VIII of the Credit Agreement as they may relate to or otherwise affect the execution, delivery or
performance of this Royalty Agreement by the Borrower, each such agreement, covenant and obligation contained in such Articles
of the Credit Agreement, and all other terms of the Credit Agreement to which reference is made in such Articles, together with
all related definitions and ancillary provisions, being hereby incorporated into this Royalty Agreement by reference as though
specifically set forth herein. In the event that the Credit Agreement terminates (in accordance with its terms or otherwise) prior
to the expiration of the Term, such agreements, covenants and obligations so incorporated by reference herein shall continue to
be in full force and effect in this Royalty Agreement, without regard to such earlier termination of the Credit Agreement (as if
such agreement remained in full force and effect).

 

Section
4.2           Maintenance of Existence; Licenses; Compliance with
Laws and Related Agreements. Holdings, Bacterin and each of the Subsidiaries shall (i) preserve and keep in full force and
effect its existence, (ii) preserve and maintain all rights, privileges, Permits and franchises necessary or desirable in the normal
conduct of its business, (iii) comply in all material respects with all Laws and Judgments applicable to it, and (iv) not breach
any Related Agreement to which such Person is a party in any respect material to the interests of ROS hereunder.

 

Section
4.3           Maintenance of Patents. Holdings, Bacterin and
each of the Subsidiaries shall prosecute and maintain, at its own expense, each Patent included in the Intellectual Property, unless
the failure to prosecute and maintain such Patent could not reasonably be expected to adversely affect the value of the Royalty
Payments.

 

Section
4.4           Enforcement of Intellectual Property. Bacterin
shall promptly inform ROS of any suspected infringement by a Third Party of any Intellectual Property that could reasonably be
expected to adversely affect in any material respect the value of the Royalty Payments. Bacterin shall provide to ROS a copy of
any written notice of any such suspected infringement of Intellectual Property delivered or received by Bacterin or any of its
Affiliates as soon as practicable and in any event not less than five Business Days following such delivery or receipt.

 

    	- 8 -

    	 

    

 

Section
4.5           Challenges to Intellectual Property. Bacterin
shall promptly inform ROS of any challenge to the Intellectual Property that could reasonably be expected to adversely affect in
any material respect the value of the Royalty Payments. Bacterin shall provide to ROS a copy of any written notice of any such
challenge to the Intellectual Property received by Bacterin or any of its Affiliates as soon as practicable and in any event not
less than five Business Days following such receipt.

 

Section
4.6           Performance of Related Agreements. Bacterin
shall not, and shall not permit any of its Affiliates to, (i) breach any Related Agreement in any respect material to the interests
of ROS or (ii) fail to use all its reasonable efforts to cure any such material breach by Bacterin or any of its Affiliates of
any Related Agreement.

 

Section
4.7           Related Agreements and Sublicense Agreements.
Promptly, and in any event within five Business Days, following Bacterin becoming aware of, or coming to believe in good faith
that there has been, a material breach of (i) any Related Agreement by a Contract Counterparty or (ii) any Sublicense Agreement
by a Third Party, in each case that could reasonably be expected to adversely affect in any material respect the value of the Royalty
Payments, Bacterin shall provide notice of such breach to ROS. In addition, Bacterin shall provide to ROS a copy of any written
notice of any such breach or alleged breach of any Related Agreement or any Sublicense Agreement delivered or received by Bacterin
or any of its Affiliates as soon as practicable and in any event not less than five Business Days following such delivery or receipt.

 

Section
4.8           Diligence. Bacterin shall, shall cause each
of its Affiliates to, and shall use commercially reasonable efforts to cause any Contract Counterparties and Sublicensees to, use
its respective best efforts to diligently make (or have made), market and sell the Products.

 

Section
4.9           Further Assurances; Information. Bacterin shall,
shall cause each of its Affiliates to, and shall use commercially reasonable efforts to cause any Contract Counterparties and Sublicensees
to, at Bacterin’s expense, furnish, execute and deliver such additional documents, certificates, instruments, and statements,
provide such additional data and information, and perform such additional acts, in each case, as may be reasonably requested by
ROS in connection with, or in furtherance of, any of the provisions of this Royalty Agreement.

 

Article
V.

EVENTS OF DEFAULT; REMEDIES

 

Section
5.1           Events of Default. The occurrence of any of
the following events shall constitute a “Royalty Event of Default” under this Royalty Agreement:

 

(a)          Bacterin
shall default in the payment (i) of any Royalty Payment when due hereunder or (ii) any other payment when due hereunder, and in
the case of clause (ii) such default shall continue for a period of two Business Days after such amount was due.

 

    	- 9 -

    	 

    

 

(b)          Any
representation or warranty of Bacterin contained or incorporated by reference herein, or in any other instrument, document, certificate,
report or statement executed and delivered in connection herewith (including any Royalty Report or any representation or warranty
incorporated by reference herein), shall at any time prove to have been incorrect in any material respect when made.

 

(c)          Any
Event of Default (as defined under the Credit Agreement) shall have occurred under Section 9.1.1, Section 9.1.7, Section 9.1.8,
Section 9.1.9, Section 9.1.11 or Section 9.1.12 of the Credit Agreement.

 

Section
5.2           Put Option. Upon the occurrence of, and during
the continuation of, any Royalty Event of Default, in addition to any other rights and remedies available to ROS under this Royalty
Agreement, any other Loan Document or otherwise, ROS shall have the right (at its option) to require Bacterin to purchase from
ROS all of its rights to the remaining Royalty Payments that will become due pursuant to Section 2.1 (the “Put
Option”). The amount payable by Bacterin to ROS in respect of the Put Option shall be the Purchase Price. If ROS elects
to exercise its Put Option, it shall so notify Bacterin in writing (the “Put Notice”), which Put Notice shall
set forth a calculation of the Purchase Price in reasonable detail. Bacterin shall, on the fifth Business Day following its receipt
of such Put Notice, pay the Purchase Price to ROS; provided, that, solely for purposes of this Section 5.2, the calculation
of the Purchase Price shall assume that all outstanding principal on the Loans, together with all accrued and unpaid interest and
fees thereon or in respect thereof, in each case if any, shall have been paid on or before the payment of such Purchase Price.
The payment of the Purchase Price pursuant to this Section 5.2 shall be made by wire transfer of immediately available funds
to an account designated by ROS.

 

Section
5.3           Other Rights and Remedies.

 

(a)          ROS
shall have the right to enforce the provisions of this Royalty Agreement or any other Loan Document by legal proceedings for the
specific performance of any covenant or agreement contained herein or for the enforcement of any other appropriate legal or equitable
remedy, and ROS may recover its costs and expenses caused by any breach by Bacterin of the provisions of this Royalty Agreement
or as a result of, or in connection with, the occurrence of any Royalty Event of Default, including court costs, attorneys’
fees and other costs and expenses incurred in the enforcement of the obligations of Bacterin, or any rights of ROS, under this
Royalty Agreement.

 

(b)          ROS
shall have the right to exercise all rights and remedies under this Royalty Agreement or any other Loan Document and all other
rights and remedies which ROS may have under applicable Law or otherwise.

 

Article
VI.

TERM

 

Section
6.1           Term. The term of this Royalty Agreement (the
“Term”) shall commence on the Closing Date and shall expire on the first anniversary of the last day of the
Royalty Term.

 

    	- 10 -

    	 

    

 

Section
6.2           Survival. The expiration of this Royalty Agreement
shall be without prejudice to any rights or obligations of the Parties that may have accrued prior to such expiration or termination,
and the provisions of Sections 6.2, 8.4, 8.5, 8.9, 8.10, 8.11 and 8.12 shall survive
the expiration of this Royalty Agreement.

 

Article
VII.

CONFIDENTIALITY

 

Section
7.1           Confidential Information. Subject to the provisions
of Section 7.2, at all times during the Term, the Receiving Party shall keep confidential and shall not publish or otherwise
disclose any Confidential Information furnished to it by the Disclosing Party, except to those of the Receiving Party’s employees,
advisors or consultants who have a need to know such information to assist such Receiving Party in the performance of such Receiving
Party’s obligations or in the exercise of such Receiving Party’s rights hereunder and who are subject to reasonable
obligations of confidentiality (collectively, “Recipients”). Notwithstanding anything to the contrary set forth
herein, ROS may disclose this Royalty Agreement and the terms and conditions hereof and any information related hereto, including
the Royalty Reports, to (i) its Affiliates, (ii) potential and actual assignees of any of ROS’ rights hereunder (including
the right to receive any Payments hereunder) and (iii) potential and actual investors in, or lenders to, ROS (including, in each
of the foregoing cases, such Person’s employees, advisors or consultants); provided that each such recipient shall
be subject to reasonable obligations of confidentiality; provided, further, that, other than during the continuance
of an Event of Default, ROS shall not disclose Bacterin’s Confidential Information, other than this Royalty Agreement, the
terms and conditions hereof and the Royalty Reports (and, in the case of its Affiliates, any other information related hereto),
to such Persons without the prior written consent of Bacterin, such consent not to be unreasonably withheld or delayed.

 

Section
7.2           Exceptions to Confidentiality. The Receiving
Party’s obligations set forth in this Royalty Agreement shall not extend to any Confidential Information of the Disclosing
Party:

 

(a)          that
is or hereafter becomes part of the public domain (other than as a result of a disclosure by the Receiving Party or its Recipients
in violation of this Royalty Agreement);

 

(b)          that
is received from a Third Party without restriction on disclosure and without, to the knowledge of the Receiving Party, breach of
any agreement between such Third Party and the Disclosing Party;

 

(c)          that
the Receiving Party can demonstrate by competent evidence was already in its possession without any limitation on disclosure prior
to its receipt from the Disclosing Party;

 

(d)          that
is generally made available to Third Parties by the Disclosing Party without restriction on disclosure;

 

(e)          that
the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party; or

 

    	- 11 -

    	 

    

 

(f)          that
is, in the opinion of counsel to the Receiving Party, required to be disclosed pursuant to Law or Judgment binding upon the Receiving
Party or pursuant to the requirement or request of any Governmental Entitiy.

 

Section
7.3           Remedies. Each Party agrees that the unauthorized
disclosure of any information by the Receiving Party in violation of this Royalty Agreement will cause severe and irreparable damage
to the Disclosing Party. In the event of any violation of this Article 7, the Receiving Party agrees that the Disclosing Party
shall be authorized and entitled to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or permanent,
without the necessity of proving irreparable harm or monetary damages, as well as any other relief permitted by applicable Law.

 

Section
7.4           Press Releases. No Party shall, and each Party
shall instruct its Affiliates not to, issue a press release or other public announcement or otherwise make any public disclosure
with respect to this Royalty Agreement or the subject matter hereof without the prior consent of the other Party hereto (which
consent shall not be unnecessarily withheld or delayed), except as may be required by applicable Law (in which case the Party required
to make the release or statement shall allow the other Party reasonable time to comment on such release or statement in advance
of such issuance).

 

Article
VIII.

MISCELLANEOUS PROVISIONS

 

Section
8.1           Loan Document. This Royalty Agreement is a Loan
Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered
and applied in accordance with the terms and provisions thereof, including Article X thereof (including Section 10.4 thereof),
which are incorporated herein by reference and deemed to apply to Bacterin, ROS and this Royalty Agreement, as applicable, throughout
the Term (whether or not, and without regard to, any earlier termination of the Credit Agreement).

 

Section
8.2           Binding on Successors, Transferees and Assigns;
Assignment. This Royalty Agreement shall remain in full force and effect until the Term has concluded and shall be binding
upon the Parties hereto and their respective successors, transferees and assigns; provided that Bacterin may not assign
or transfer any of its rights or obligations hereunder without the prior written consent of ROS.

 

Section
8.3           Amendments, etc. No amendment to or waiver of
any provision of this Royalty Agreement, nor consent to any departure by Bacterin from its obligations under this Royalty Agreement,
shall in any event be effective unless the same shall be in writing and signed by ROS, and then such waiver or consent shall be
effective only in the specific instance and for the specific purpose for which given.

 

Section
8.4           Notices. All notices and other communications
provided for hereunder shall be given or made as set forth in Section 10.2 of the Credit Agreement.

 

Section
8.5           No Waiver; Remedies. No failure on the part
of ROS to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or
partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. The
remedies herein provided are cumulative and not exclusive of any remedies provided by Law.

 

    	- 12 -

    	 

    

 

Section
8.6           Section Captions. Section captions used in this
Royalty Agreement are for convenience of reference only and shall not affect the construction of this Royalty Agreement.

 

Section
8.7           Severability. Any provision of this Royalty
Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Royalty Agreement or
affecting the validity or enforceability of such provision in any other jurisdiction.

 

Section
8.8           Governing Law, Entire Agreement, etc. THIS ROYALTY
AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING
OUT OF OR RELATING TO THIS ROYALTY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE
OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This
Royalty Agreement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect
to the subject matter hereof and supersedes any prior agreements, written or oral, with respect hereto.

 

Section
8.9           Forum Selection and Consent to Jurisdiction.
ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS ROYALTY AGREEMENT, OR ANY COURSE OF CONDUCT,
COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE LENDER OR ANY GUARANTOR IN CONNECTION HEREWITH, SHALL
BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN THE STATE OF NEW YORK OR IN THE
UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; PROVIDED THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY
COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE OPTION OF ROS, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER
PROPERTY MAY BE FOUND. BACTERIN IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL
SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK AT THE ADDRESS FOR NOTICES SPECIFIED IN SECTION 10.2 OF THE CREDIT AGREEMENT.
BACTERIN HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY HAVE OR HEREAFTER
MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH
LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE EXTENT THAT BACTERIN HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM
JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT
IN AID OF EXECUTION OR OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, BACTERIN HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT
PERMITTED BY LAW SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER THIS ROYALTY AGREEMENT.

 

    	- 13 -

    	 

    

 

Section
8.10         Counterparts. This Royalty Agreement may be executed by
the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one
and the same agreement. This Royalty Agreement shall become effective when counterparts hereof executed on behalf of Bacterin and
ROS shall have been received by ROS. Delivery of an executed counterpart of a signature page to this Royalty Agreement by email
(e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of
this Royalty Agreement.

 

Section
8.11         Waiver of Jury Trial. BACTERIN AND ROS HEREBY KNOWINGLY,
VOLUNTARILY AND INTENTIONALLY WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS ROYALTY AGREEMENT, OR ANY COURSE OF CONDUCT,
COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF BACTERIN OR ROS IN CONNECTION HEREWITH. BACTERIN ACKNOWLEDGES
AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION FOR THIS PROVISION (AND EACH OTHER PROVISION OF EACH OTHER LOAN
DOCUMENT TO WHICH IT IS A PARTY) AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR ROS TO ENTER INTO THIS ROYALTY AGREEMENT,
THE CREDIT AGREEMENT AND EACH OTHER LOAN DOCUMENT.

 

Section
8.12         Relationship of the Parties. The status of a Party under
this Royalty Agreement shall be that of an independent contractor. Nothing contained in this Royalty Agreement shall be construed
as creating a partnership, joint venture or agency relationship between Bacterin or any of its Affiliates, on the one hand, and
ROS or any of its Affiliates, on the other hand. Except to the limited extent expressly provided in this Royalty Agreement, no
Party hereto shall have the authority to bind, obligate or represent any other Party hereto.

 

[Signature Page Follows]

 

    	- 14 -

    	 

    

 

IN WITNESS WHEREOF, the Parties have executed
this Royalty Agreement on the day and year first above written.

 

	 	BACTERIN INTERNATIONAL, INC.
	 	 
	 	By:	/s/ John P. Gandolfo
	 	Name:	John P. Gandolfo
	 	Title:	Chief Financial Officer
	 	 
	 	ROS ACQUISITION OFFSHORE LP
	 	By ROS Acquisition Offshore GP Ltd.,
	 	its General Partner
	 	By OrbiMed Advisors LLC,
	 	its investment manager
	 	 
	 	By:	/s/ Samuel D. Isaly
	 	Name:	Samuel D. Isaly
	 	Title:	Managing Member

 

Signature Page to Royalty AgreementEXECUTION VERSION

 

CONTRIBUTION AND EXCHANGE AGREEMENT

 

Dated as of August 24, 2012

 

by and among

 

ICAHN ENTERPRISES L.P.,

 

BECKTON CORP.,

 

BARBERRY CORP.,

 

High
River Limited Partnership

 

and

 

Koala
Holding LP 

 

    	 

    	 

    

 

Table of Contents

 

	 	 	Page
	 	 	 
	ARTICLE I
	 
	Terms of the Transaction
	 	 	 
	Section 1.1	Contribution of Contribution Shares	1
	Section 1.2	Consideration.	1
	Section 1.3	Closing	2
	Section 1.4	Actions at the Closing	2
	Section 1.5	Adjustments	2
	Section 1.6	Tax Treatment	3
	Section 1.7	704(c) Methods	3
	 	 	 
	ARTICLE II
	 
	Representations and Warranties of Contributing Parties Relating to Contributing
    Parties
	 	 	 
	Section 2.1	Organization of Contributing Parties	3
	Section 2.2	Authority	3
	Section 2.3	Title	3
	Section 2.4	No Conflicts	4
	Section 2.5	Governmental Consents and Approvals	4
	Section 2.6	Brokers	4
	Section 2.7	No Purchases or Sales	5
	 	 	 
	ARTICLE III
	 
	Representations and Warranties of Barberry Relating to Barberry
	 	 	 
	Section 3.1	Net Worth of Barberry	5
	 	 	 
	ARTICLE IV
	 
	Representations and Warranties of Beckton Relating to Beckton
	 	 	 
	Section 4.1	Organization	5
	Section 4.2	Authority	5
	Section 4.3	No Conflicts	5
	Section 4.4	Governmental Consents and Approvals	6
	Section 4.5	Brokers	6
	Section 4.6	No Purchases or Sales	6

 

    	i

    	 

    

 

Table of Contents

(continued)

 

	 	 	Page
	 	 	 
	ARTICLE V
	 
	Representations and Warranties of IEP
	 	 	 
	Section 5.1	Organization of IEP	7
	Section 5.2	Authority	7
	Section 5.3	No Conflicts	7
	Section 5.4	Consents and Approvals	7
	Section 5.5	Brokers	8
	Section 5.6	Title	8
	 	 	 
	ARTICLE VI
	 
	Covenants
	 	 	 
	Section 6.1	Efforts to Consummate Transaction.	8
	 	 	 
	ARTICLE VII
	 
	Conditions to Closing
	 	 	 
	Section 7.1	Conditions to Obligations of the Contributing Parties	9
	Section 7.2	Conditions to Obligations of IEP	9
	 	 	 
	ARTICLE VIII
	 
	Indemnification
	 	 	 
	Section 8.1	Indemnification by Barberry.	10
	Section 8.2	Claims	11
	Section 8.3	Notice of Third Party Claims; Assumption of Defense	12
	Section 8.4	Settlement or Compromise	12
	Section 8.5	Failure of Barberry to Act	12
	Section 8.6	Tax Character	13
	Section 8.7	Sole and Exclusive Remedy	13
	 	 	 
	ARTICLE IX
	 
	Definitions
	 	 	 
	Section 9.1	Defined Terms	13

 

    	ii

    	 

    

 

 

Table of Contents

(continued)

 

	 	 	Page
	 	 	 
	ARTICLE X
	 
	Miscellaneous
	 	 	 
	Section 10.1	Investigation	17
	Section 10.2	Survival of Representations and Warranties	18
	Section 10.3	Entire Agreement	18
	Section 10.4	Waiver	18
	Section 10.5	Amendment	18
	Section 10.6	No Third Party Beneficiary	18
	Section 10.7	Assignment; Binding Effect	18
	Section 10.8	Headings	18
	Section 10.9	Invalid Provisions	19
	Section 10.10	Governing Law	19
	Section 10.11	Counterparts	19
	Section 10.12	Waiver of Jury Trial	19
	Section 10.13	Consent to Jurisdiction	19
	Section 10.14	Expenses	20
	Section 10.15	Notices	20
	Section 10.16	Further Assurances	21
	 	 	 
	Schedules	 	 
	 	 	 
	Schedule 1.1	Contribution and Exchange	 
	Schedule 3.1	Net Worth of Barberry	 
	 	 	 
	IEP Disclosure Schedule	 

 

    	iii

    	 

    

 

CONTRIBUTION AND EXCHANGE AGREEMENT

 

THIS CONTRIBUTION AND EXCHANGE AGREEMENT
(this “Agreement”), dated as of August 24, 2012, is by and among Icahn Enterprises L.P., a Delaware limited
partnership (“IEP”), Beckton Corp., a Delaware corporation (“Beckton”), Barberry Corp.,
a Delaware corporation (“Barberry”), High River Limited Partnership, a Delaware limited partnership (“High
River”), and Koala Holding LP, a Delaware limited partnership (“Koala,” together with High River,
the “Contributing Parties,” each a “Contributing Party”). Capitalized terms not otherwise
defined herein have the meanings set forth in Article IX.

 

RECITALS:

 

WHEREAS, IEP
Energy LLC (the “Company”) owns 71,198,718 shares of common stock of CVR Energy, Inc. (“CVR”),
which shares currently represent approximately 82% of the total issued and outstanding shares of common
stock of CVR (“CVR Stock”);

 

WHEREAS, the Contributing Parties collectively
own approximately 6.41% of the membership interests in the Company (the “LLC Shares”) on account of their contribution
of 4,566,546 shares of CVR Stock to the Company; and

 

WHEREAS, the Contributing Parties desire
to contribute to IEP, and IEP desires to receive from the Contributing Parties, the LLC Shares (the “Contribution Shares”)
upon the terms and subject to the conditions in this Agreement;

 

NOW, THEREFORE, the parties hereto agree
as follows:

 

ARTICLE I

 

Terms of the
Transaction

 

Section 1.1           Contribution
of Contribution Shares. At the Closing, and on the terms set forth in this Agreement, the Contributing Parties shall cause
the Contribution Shares to be contributed, assigned, transferred, conveyed and delivered to IEP in the number of LLC Shares set
forth opposite each Contributing Party’s name on Schedule 1.1, and IEP shall receive and accept the Contribution
Shares.

 

Section 1.2           Consideration.
The consideration to be issued, transferred, conveyed and delivered by IEP to the Contributing Parties at the Closing in exchange
for the contribution of the Contribution Shares to IEP shall equal 3,288,371 fully paid and nonassessable IEP Units, for an aggregate
consideration of 3,288,371 IEP Units (the “Exchange Units”). The Exchange Units shall be allocated among the
Contributing Parties as set forth on Schedule 1.1.

 

    	1

    	 

    

 

Section 1.3           Closing.
The closing of the transactions contemplated by Section 1.1 and Section 1.2 hereof (the “Closing”)
shall take place (a) at the offices of IEP, located at White Plains Plaza, 445 Hamilton Avenue – Suite 1210,
White Plains, NY 10601, immediately after all the conditions set forth in Article VII are satisfied or waived (other than
those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or waiver of those conditions
at the Closing), or (b) at such other time, date or place as the parties may agree. The date on which the Closing
occurs is herein referred to as the “Closing Date”. The Closing shall be deemed effective for all accounting,
financial and reporting purposes as of the close of business on the Closing Date.

 

Section 1.4           Actions
at the Closing. At the Closing: (i) IEP shall issue and deliver to each Contributing Party a certificate or certificates
representing the Exchange Units to be received by such Contributing Party pursuant to Section 1.2, or, in the case of any
Exchange Units that are held in book-entry form, IEP shall cause such Exchange Units to be transferred to the account designated
in writing by such Contributing Party; (ii) each Contributing Party shall deliver to IEP the Contribution Shares it
is contributing pursuant to Section 1.1, together with instruments of transfer satisfactory to IEP or, in the case of any
Contribution Shares that are held in book-entry form, such Contributing Party shall cause such Contribution Shares to be transferred
to the account designated in writing by IEP; (iii) if requested by IEP, each Contributing Party shall deliver to IEP a
statement, meeting the requirements of section 1.1445-2(b)(2) of the Treasury regulations, to the effect that such Contributing
Party is not a foreign person; (iv) pursuant to Section 5.1 of the IEP Registration Rights Agreement, each Contributing
Party shall deliver to IEP an executed signature page to the IEP Registration Rights Agreement (the “IEP Registration
Rights Joinder”); (v) IEP shall acknowledge, by signing the IEP Registration Rights Joinder, that, as a
result of the Contributing Parties’ delivery of the IEP Registration Rights Joinder, the Contributing Parties shall be and
shall be deemed to be each a “Holder” under the IEP Registration Rights Agreement for all purposes thereunder; (vi) IEP
shall deliver or cause to be delivered to the Contributing Parties evidence that the Nasdaq has approved the Exchange Units for
listing, subject only to official notice of issuance, in form and substance reasonably acceptable to Contributing Parties; and
(vii) Beckton shall cause Icahn Enterprises GP Holdings LP (“IEGP”), the general partner of IEP
to make such contribution to IEP as is necessary for IEGP to maintain a 1% general partnership interest in IEP.

 

Section 1.5           Adjustments.
In the event that the number of LLC Shares or IEP Units, or securities convertible or exchangeable into or exercisable for LLC
Shares or IEP Units, issued and outstanding prior to (and including) the Closing Date changes as a result of a reclassification,
stock or unit split (including a reverse stock or unit split), stock or unit dividend or stock or unit distribution, recapitalization,
merger, subdivision, issuer tender or exchange offer, or other similar transaction, the LLC Shares and/or IEP Units to be delivered
as consideration hereunder, as applicable, shall be proportionately and equitably adjusted to account for such change.

 

    	2

    	 

    

 

Section 1.6           Tax
Treatment. The parties agree and acknowledge that the contribution of the Contribution Shares to IEP in exchange for the Exchange
Units is intended to qualify as a tax-free contribution to a partnership under Code Section 721(a) and no party, on a Tax Return
or otherwise, shall, except to the extent required by Law, take any position inconsistent with such treatment.

 

Section 1.7           704(c)
Methods. Beckton will cause IEGP, to the extent possible, to take such action as is necessary, including selecting methods
under Code Section 704(c), to cause each Exchange Unit to have the same economic and tax characteristics to any purchaser or acquiror
thereof as each other IEP Unit, provided that Beckton consults with the Audit Committee with respect to all Code Section
704(c) elections relating to this transaction.

 

ARTICLE II

 

Representations
and Warranties of Contributing Parties Relating to Contributing Parties

 

Each Contributing Party hereby makes the
following representations and warranties contained in this Article II to IEP.

 

Section 2.1           Organization
of Contributing Parties. Such Contributing Party is a limited partnership duly organized, validly existing and in good standing
under the Laws of the State of Delaware. Such Contributing Party has full organizational power and authority to execute and deliver
this Agreement and to perform its obligations hereunder and to consummate the transactions contemplated hereby. Such Contributing
Party is an Affiliate (as defined under the IEP Registration Rights Agreement) of a Holder (as defined under the IEP Registration
Rights Agreement).

 

Section 2.2           Authority.
The execution and delivery by such Contributing Party of this Agreement, and the performance by such Contributing Party of its
obligations hereunder, have been duly and validly authorized by all requisite limited partnership action on the part of such Contributing
Party and no other action on the part of such Contributing Party is necessary for such execution, delivery or performance. This
Agreement has been duly and validly executed and delivered by such Contributing Party and constitutes a legal, valid and binding
obligation of such Contributing Party, enforceable against such Contributing Party in accordance with its terms.

 

Section 2.3           Title.
Such Contributing Party is the sole owner of the Contribution Shares set forth opposite its name on Schedule 1.1 and has
good and valid title to such Contribution Shares, free and clear of all Liens. The delivery of such Contribution Shares and other
instruments of transfer delivered by such Contributing Party to IEP at the Closing will transfer to IEP good and valid title to
the Contribution Shares owned by such Contributing Party immediately prior to the Closing, free and clear of all Liens.

 

    	3

    	 

    

 

Section 2.4           No
Conflicts. The execution and delivery by such Contributing Party of this Agreement do not, and the performance by such Contributing
Party of its obligations under this Agreement and the consummation of the transactions contemplated hereby will not:

 

(a)          conflict
with or result in a violation or breach of any of the terms, conditions or provisions of the organizational documents of such
Contributing Party;

 

(b)          conflict
with or result in a violation or breach of any term or provision of any Law or Order applicable to such Contributing Party;

 

(c)          (i)
conflict with or result in a violation or breach of, (ii) constitute (with or without notice or lapse of time or both)
a default under, (iii) require such Contributing Party to obtain any consent, approval or action of, make any filing
(other than with the SEC pursuant to Section 13 and Section 16 of the Exchange Act) with or give any notice to any Person, as
a result or under the terms of, or (iv) result in or give to any Person any right of termination, cancellation, acceleration
or modification in or with respect to, any Contract or License to which such Contributing Party is a party; or

 

(d)          result
in the creation or imposition of any Lien upon the Contribution Shares.

 

Section 2.5           Governmental
Consents and Approvals. Other than compliance with any applicable foreign or state securities or blue sky Laws, no consent,
authorization or approval of, filing (other than with the SEC pursuant to Section 13 and Section 16 of the Exchange Act) or registration
with, or cooperation from, any Governmental or Regulatory Authority is necessary in connection with the execution, delivery and
performance by such Contributing Party of this Agreement or the consummation of the transactions contemplated hereby.

 

Section 2.6           Brokers.
Such Contributing Party has not used any broker or finder in connection with the transactions contemplated hereby, and neither
IEP nor any of its Affiliates has or shall have any liability or otherwise suffer or incur any Loss as a result of or in connection
with any brokerage or finder’s fee or other commission of any Person retained or purporting to be retained by such Contributing
Party in connection with any of the transactions contemplated by this Agreement.

 

    	4

    	 

    

 

Section 2.7           No
Purchases or Sales. Other than the acquisition or disposition of LLC Shares, CVR Stock or IEP Units from or to Affiliates,
no Contributing Party nor any of its Affiliates has directly or indirectly acquired or disposed of any CVR Stock or IEP Units
during the 60 days preceding the date hereof.

 

ARTICLE III

 

Representations
and Warranties of Barberry Relating to Barberry

 

Barberry hereby makes the following representations
and warranties contained in this Article III to IEP.

 

Section 3.1           Net
Worth of Barberry. Schedule 3.1 sets forth the net worth of Barberry as of the date hereof.

 

ARTICLE IV

 

Representations
and Warranties of Beckton Relating to Beckton

 

Beckton hereby makes the following representations
and warranties contained in this Article IV to IEP.

 

Section 4.1           Organization.
Beckton is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware. Beckton
has full organizational power and authority to execute and deliver this Agreement and to perform its obligations hereunder and
to consummate the transactions contemplated hereby.

 

Section 4.2           Authority.
The execution and delivery by Beckton of this Agreement, and the performance by Beckton of its obligations hereunder, has been
duly and validly authorized by Beckton’s board of directors and no other action on the part of Beckton or its shareholders
is necessary for such execution, delivery or performance. This Agreement has been duly and validly executed and delivered by Beckton
and constitutes a legal, valid and binding obligation of Beckton, enforceable against Beckton in accordance with its terms.

 

Section 4.3           No
Conflicts. The execution and delivery by Beckton of this Agreement does not, and the performance by Beckton of its obligations
under this Agreement and the consummation of the transactions contemplated hereby will not:

 

(a)          conflict
with or result in a violation or breach of any of the terms, conditions or provisions of the organizational documents of Beckton;

 

(b)          conflict
with or result in a violation or breach of any term or provision of any Law or Order applicable to Beckton; or

 

    	5

    	 

    

 

(c)          (i)
conflict with or result in a violation or breach of, (ii) constitute (with or without notice or lapse of time or both)
a default under, (iii) require Beckton to obtain any consent, approval or action of, make any filing (other than with
the SEC pursuant to Section 13 and Section 16 of the Exchange Act) with or give any notice to any Person, as a result or under
the terms of, or (iv) result in or give to any Person any right of termination, cancellation, acceleration or modification
in or with respect to, any Contract or License to which Beckton is a party.

 

Section 4.4           Governmental
Consents and Approvals. Other than (i) compliance with any applicable foreign or state securities or blue sky
Laws and (ii) the filings or notices that are required and customary pursuant to any state environmental transfer
statutes, no consent, authorization or approval of, filing (other than with the SEC pursuant to Section 13 and Section 16 of the
Exchange Act) or registration with, or cooperation from, any Governmental or Regulatory Authority is necessary in connection with
the execution, delivery and performance by Beckton of this Agreement or the consummation of the transactions contemplated hereby.

 

Section 4.5           Brokers.
Beckton has not used any broker or finder in connection with the transactions contemplated hereby, and neither IEP nor any of
its Affiliates has or shall have any liability or otherwise suffer or incur any Loss as a result of or in connection with any
brokerage or finder’s fee or other commission of any Person retained or purporting to be retained by Beckton in connection
with any of the transactions contemplated by this Agreement.

 

Section 4.6           No
Purchases or Sales. Other than the acquisition or disposition of LLC Shares, CVR Stock or IEP Units from or to Affiliates,
neither Beckton nor any of its Affiliates has directly or indirectly acquired or disposed of any LLC Shares, CVR Stock or IEP
Units during the 60 days preceding the date hereof.

 

ARTICLE V

 

Representations
and Warranties of IEP

 

Except as set forth on the IEP disclosure
schedule (if any) delivered by IEP to the Contributing Parties concurrently with the execution and delivery of this Agreement
(the “IEP Disclosure Schedule”), IEP hereby makes the following representations and warranties contained in
this Article V to the Contributing Parties. The IEP Disclosure Schedule is arranged and numbered to correspond to the numbered
and lettered paragraphs contained in this Article V. Unless otherwise specified herein, disclosure made in any particular
Section of the IEP Disclosure Schedule shall be deemed made in any other Section or Sections of the IEP Disclosure Schedule to
which the relevance of such disclosure is readily apparent on its face from the text of such disclosure.

 

    	6

    	 

    

 

Section 5.1           Organization
of IEP. IEP is a limited partnership duly formed, validly existing and in good standing under the Laws of the State of Delaware.
IEP has full organizational power and authority to execute and deliver this Agreement and to perform its respective obligations
hereunder and to consummate the transactions contemplated hereby.

 

Section 5.2           Authority.
The execution and delivery by IEP of this Agreement, and the performance by IEP of its obligations hereunder, have been duly and
validly authorized and no other action on the part of IEP or IEP’s general partner is necessary. This Agreement has been
duly and validly executed and delivered by IEP and constitutes a legal, valid and binding obligation of IEP enforceable against
IEP in accordance with its terms.

 

Section 5.3           No
Conflicts. The execution and delivery by IEP of this Agreement do not, and the performance by IEP of its obligations under
this Agreement and the consummation of the transactions contemplated hereby, will not:

 

(a)          conflict
with, or result in a violation or breach of, any of the terms, conditions or provisions of the organizational documents of IEP;

 

(b)          conflict
with, or result in a violation or breach of, any term or provision of any Law or Order applicable to IEP; or

 

(c)          (i)
conflict with, or result in a violation or breach of, (ii) constitute (with or without notice or lapse of time or
both) a default under, (iii) require IEP to obtain any consent, approval or action of, make any filing (other than
with the SEC pursuant to Section 13 and Section 16 of the Exchange Act) with or give any notice to any Person as a result or under
the terms of, (iv) result in or give to any Person any right of termination, cancellation, acceleration or modification
in or with respect to, or (v) result in the creation or imposition of any Lien upon IEP or any of its Assets and Properties
under, any Contract or License to which IEP is a party or by which any of its Assets and Properties are bound.

 

Section 5.4           Consents
and Approvals. No consent, authorization or approval of, filing (other than with the SEC pursuant to Section 13 and Section
16 of the Exchange Act) or registration with, or cooperation from, any Governmental or Regulatory Authority or any other Person
not a party to this Agreement is necessary in connection with the execution, delivery and performance by IEP of this Agreement
or the consummation of the transactions contemplated hereby.

 

    	7

    	 

    

 

Section 5.5           Brokers.
IEP has not used any broker or finder in connection with the transactions contemplated hereby, and each of the Contributing Parties,
the Company and CVR, and each of their Affiliates, does not have and shall not have any liability nor shall any of them otherwise
suffer or incur any Loss as a result of or in connection with any brokerage or finder’s fee or other commission of any Person
retained or purporting to be retained by IEP in connection with any of the transactions contemplated by this Agreement.

 

Section 5.6           Title.
The Exchange Units have been duly authorized by all required action on the part of IEP. The delivery of the Exchange Units delivered
by IEP to the Contributing Parties at the Closing will transfer to the Contributing Parties good and valid title to the Exchange
Units free and clear of all Liens, other than any Liens created by any Contributing Party.

 

ARTICLE VI

 

Covenants

 

Section 6.1           Efforts
to Consummate Transaction.

 

(a)          From
the date hereof through the Closing Date, upon the terms and subject to the conditions set forth in this Agreement, each of the
parties hereto shall use its commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to
be done, and to assist and cooperate with the other parties in doing, all things necessary, proper or advisable under applicable
Laws and regulations to consummate and make effective the transactions contemplated by this Agreement. The parties will use their
commercially reasonable efforts and cooperate with one another (i) in promptly determining whether any filings are required
to be made or consents, approvals, waivers, licenses, permits or authorizations are required to be obtained (or, which if not
obtained, would result in a Material Adverse Effect or an event of default, termination or acceleration of any agreement or any
put right under any agreement) under any applicable Law or regulation or from any Governmental or Regulatory Authority or third
parties, and (ii) in promptly making any such filings, in furnishing information required in connection therewith and in
timely seeking to obtain any such consents, approvals, permits or authorizations.

 

    	8

    	 

    

 

(b)          From
the date hereof through the Closing Date, the Contributing Parties shall give prompt written notice to IEP of: (i) any
occurrence, or failure to occur, of any event whose occurrence or failure to occur would reasonably be expected to cause any representation
or warranty of the Contributing Parties contained in this Agreement, if made on or as of the date of such event or as of the Closing
Date, to be untrue or inaccurate, except for changes permitted by this Agreement and except to the extent that any representation
and warranty is made as of a specified date, in which case, such representation and warranty shall be true, complete and accurate
as of such date; or (ii) any failure of the Contributing Parties or of any officer, member, director, employee, consultant
or agent of the Contributing Parties, to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied
by it or them under this Agreement; provided, however, that no such notification shall affect the representations
or warranties of the Contributing Parties or the conditions to the obligations of IEP hereunder. From the date hereof through
the Closing Date, IEP shall give prompt written notice to the Contributing Parties of: (i) any occurrence, or failure to
occur, of any event whose occurrence or failure to occur would reasonably be expected to cause any representation or warranty
of IEP contained in this Agreement, if made on or as of the date of such event or as of the Closing Date, to be untrue or inaccurate,
except for changes permitted by this Agreement and except to the extent that any representation and warranty is made as of a specified
date, in which case, such representation and warranty shall be true, complete and accurate as of such date; or (ii) any
failure of IEP or any officer, general partner, director, employee, consultant or agent of IEP, to comply with or satisfy any
covenant, condition or agreement to be complied with or satisfied by it or them under this Agreement; provided, however,
that no such notification shall affect the representations or warranties of IEP or the conditions to the obligations of the Contributing
Parties hereunder.

 

ARTICLE VII

 

Conditions
to Closing

 

Section 7.1           Conditions
to Obligations of the Contributing Parties.

 

(a)          Representations
and Warranties; Covenants. (i) Each of the representations and warranties of IEP contained in this Agreement shall
have been accurate, true and correct on and as of the date hereof, and shall also be accurate, true and correct in all material
respects on and as of the Closing Date with the same force and effect as though made by IEP as of the Closing Date (other than
the representations and warranties made as of a specific date, which representations and warranties shall have been true and correct
only as of such date); (ii) the covenants contained in this Agreement that are to be complied with by IEP on or before
the Closing shall have been complied with in all material respects; and (iii) the Contributing Parties shall have received
a certificate dated the Closing Date of IEP signed by a duly authorized representative of IEP stating that the conditions specified
in clauses (i) and (ii) of this Section 7.1(a) have been satisfied.

 

(b)          No
IEP Material Adverse Effect. Since the date of this Agreement, no event, fact or circumstance shall have occurred or exist
that would constitute, or would reasonably be expected to have, a Material Adverse Effect on IEP.

 

Section 7.2           Conditions
to Obligations of IEP. The obligations of IEP to consummate the transactions contemplated by this Agreement shall be subject
to the fulfillment or waiver, at or prior to the Closing, of each of the following conditions:

 

    	9

    	 

    

 

(a)          Representations
and Warranties; Covenants. (i) Each of the representations and warranties contained in Articles II, III
or IV of this Agreement shall have been accurate, true and correct on and as of the date hereof, and shall also be accurate,
true and correct in all material respects on and as of the Closing Date with the same force and effect as though made as of the
Closing Date (other than the representations and warranties made as of a specific date, which representations and warranties shall
have been true and correct only as of such date); (ii) the covenants contained in this Agreement that are to be complied
with by the Contributing Parties on or before the Closing shall have been complied with in all material respects; and (iii)
IEP shall have received a certificate dated the Closing Date of the Contributing Parties and Beckton, signed by a duly authorized
representative of each Contributing Party and Beckton, stating that the conditions specified in clauses (i) and (ii) of this Section
7.2(a) have been satisfied.

 

(b)          No
Material Adverse Effect. Since the date of this Agreement, no event, fact or circumstance shall have occurred or exist that
would constitute, or would reasonably be expected to have, a Material Adverse Effect.

 

ARTICLE VIII

 

Indemnification

 

Section 8.1           Indemnification
by Barberry.

 

(a)          Barberry
agrees to indemnify IEP and its Affiliates and their respective officers, directors, employees, independent contractors, stockholders,
principals, partners, agents, or representatives (other than Carl C. Icahn and his Affiliates other than Icahn Enterprises G.P.
Inc. and its controlled Affiliates; provided, however, that for all purposes of this Article VIII, the Company,
CVR, and their controlled Affiliates shall not be deemed to be Affiliates of Icahn Enterprises G.P. Inc.) (each an “Indemnified
Person” and collectively, the “Indemnified Persons”) against, and to hold each Indemnified Person
harmless from, any and all Losses incurred or suffered by any Indemnified Person relating to or arising out of or in connection
with (i) any breach of or any inaccuracy in any representation or warranty made by any Contributing Party in this
Agreement or (ii) any breach of or failure by any Contributing Party to perform any of its covenants or obligations
set out or contemplated in this Agreement.

 

(b)          Notwithstanding
any provisions to the contrary contained herein, (x) indemnification for Losses under Section 8.1(a) shall
be payable by Barberry only if the aggregate amount of all Losses incurred by the Indemnified Persons shall exceed the Basket
Amount, at which time all such Losses, including any Losses comprising the Basket Amount, shall be recoverable and (y) the
aggregate liability of Barberry for indemnification of IEP under Section 8.1(a) shall in no event exceed the Cap Amount.

 

    	10

    	 

    

 

(c)          For
purposes of this Article VIII, any inaccuracy in or breach of any representation or warranty shall be determined without
regard to any materiality, “Material Adverse Effect”, “Material Adverse Change” or similar qualification,
and without regard to any qualification or requirement that a matter be or not be “reasonably expected” to occur, contained
in or otherwise applicable to such representation or warranty.

 

Section 8.2           Claims.
As promptly as is reasonably practicable after becoming aware of a claim for indemnification under this Agreement, the Indemnified
Person shall promptly give notice to Barberry of such claim and the amount the Indemnified Person will be entitled to receive hereunder
from Barberry; provided that the failure of the Indemnified Person to promptly give notice shall not relieve Barberry of
its obligations except to the extent (if any) that Barberry shall have been prejudiced thereby. If Barberry does not object in
writing to such indemnification claim within thirty (30) days of receiving notice thereof, the Indemnified Person shall be
entitled to recover, on the thirty-fifth day after such notice was given, from Barberry the amount of such claim, and no later
objection by Barberry shall be permitted; if Barberry agrees that it has an indemnification obligation but objects that it is obligated
to pay only a lesser amount, the Indemnified Person shall nevertheless be entitled to recover, on the thirty-fifth day after such
notice was given, from Barberry the lesser amount, without prejudice to the Indemnified Person’s claim for the difference.
In addition to the amounts recoverable by the Indemnified Person from Barberry pursuant to the foregoing provisions, the Indemnified
Person shall also be entitled to recover from Barberry interest on such amounts at the rate of Two Times Prime from, and including,
the thirty-fifth day after such notice of an indemnification claim is given to, but not including, the date such recovery is actually
made by the Indemnified Person.

 

    	11

    	 

    

 

Section 8.3           Notice
of Third Party Claims; Assumption of Defense. The Indemnified Person shall give notice as promptly as is reasonably practicable
to Barberry of the assertion of any claim, or the commencement of any suit, action or proceeding, by any Person not a party hereto
(a “Third Party Claim”) in respect of which indemnity may be sought under this Agreement; provided that
the failure of the Indemnified Person to promptly give notice shall not relieve Barberry of its obligations except to the extent
(if any) that Barberry shall have been prejudiced thereby. Barberry may, at its own expense, participate in the defense of any
Third Party Claim, suit, action or proceeding (a) upon notice to the Indemnified Person and (b) upon delivery
by Barberry to the Indemnified Person a written agreement that the Indemnified Person is entitled to indemnification for all Losses
arising out of such Third Party Claim, suit, action or proceeding and that Barberry shall be liable for the entire amount of any
Loss, at any time during the course of any such Third Party Claim, suit, action or proceeding, assume the defense thereof; provided,
however, that (i) Barberry’s counsel is reasonably satisfactory to the Indemnified Person, and (ii) Barberry
shall thereafter consult with the Indemnified Person upon the Indemnified Person’s reasonable request for such consultation
from time to time with respect to such Third Party Claim, suit, action or proceeding. If Barberry assumes such defense, the Indemnified
Person shall have the right (but not the duty) to participate in the defense thereof and to employ counsel, at its own expense,
separate from the counsel employed by Barberry. If, however, the Indemnified Person reasonably determines in its judgment that
representation by Barberry’s counsel of both Barberry and the Indemnified Person would present such counsel with a conflict
of interest, then such Indemnified Person may employ separate counsel to represent or defend it in any such Third Party Claim,
action, suit or proceeding and Barberry shall pay all of the fees and disbursements in connection with the retention of such separate
counsel. If Barberry fails to promptly notify the Indemnified Party that Barberry desires to defend the Third Party Claim pursuant,
or if Barberry gives such notice but fails to prosecute vigorously and diligently or settle the Third Party Claim, then the Indemnified
Party will have the right to defend, at the sole cost and expense of Barberry, the Third Party Claim by all appropriate proceedings,
which proceedings will be prosecuted by the Indemnified Person in good faith or will be settled at the discretion of the Indemnified
Person (with the consent of Barberry, which consent will not be unreasonably withheld). The Indemnified Person will have full control
of such defense and proceedings, including any compromise or settlement thereof. Whether or not Barberry chooses to defend or prosecute
any such Third Party Claim, suit, action or proceeding, all of the parties hereto shall cooperate in the defense or prosecution
thereof.

 

Section 8.4           Settlement
or Compromise. Any settlement or compromise made or caused to be made by the Indemnified Person or Barberry, of any claim,
suit, action or proceeding shall also be binding upon Barberry or the Indemnified Person, as the case may be, in the same manner
as if a final judgment or decree had been entered by a court of competent jurisdiction in the amount of such settlement or compromise
thereof; provided, however, that no obligation, restriction or Loss shall be imposed on the Indemnified Person as
a result of such settlement without its prior written consent. The Indemnified Person will give Barberry at least thirty (30) days
notice of any proposed settlement or compromise of any Third Party Claim, suit, action or proceeding it is defending, during which
time Barberry may reject such proposed settlement or compromise; provided, however, that from and after such rejection,
Barberry shall be obligated to assume the defense of and full and complete liability and responsibility for such Third Party Claim,
suit, action or proceeding and any and all Losses in connection therewith in excess of the amount of unindemnifiable Losses which
the Indemnified Person would have been obligated to pay under the proposed settlement or compromise.

 

Section 8.5           Failure
of Barberry to Act. In the event that Barberry does not assume the defense of any Third Party Claim, suit, action or proceeding
brought against an Indemnified Person, then any failure of the Indemnified Person to defend or to participate in the defense of
any such Third Party Claim, suit, action or proceeding or to cause the same to be done, shall not relieve Barberry of any of its
obligations under this Agreement.

 

    	12

    	 

    

 

Section 8.6           Tax
Character. The parties agree that any payments made to IEP pursuant to this Article VIII will be treated for federal
and state income tax purposes as a tax-free contribution to IEP in exchange for the Exchange Units under Code Section 721(a) and
no party, on a Tax Return or otherwise, shall, except to the extent required by Law, take any position inconsistent with such treatment.

 

Section 8.7           Sole
and Exclusive Remedy. The indemnification remedy provided by Barberry to the Indemnified Persons under this Article VIII
shall be the sole and exclusive remedy to which IEP and each other Indemnified Person shall be entitled after the Closing under
this Agreement. Any amounts owed by Barberry to an Indemnified Person under this Article VIII may be paid by Barberry, in
its sole discretion, in cash, IEP Units, or a combination of cash and IEP Units. For purposes of determining the number of IEP
Units which are to be delivered to an Indemnified Person upon settlement of an indemnification claim in whole or in part with IEP
Units, the value of each IEP Unit shall be deemed to be $39.77.

 

ARTICLE IX

 

Definitions

 

Section 9.1           Defined
Terms. As used in this Agreement, the following defined terms have the meanings indicated below:

 

“Affiliate”
means, with respect to any specified Person, any other Person that, directly or indirectly, owns or controls, is under common ownership
or control with, or is owned or controlled by, such specified Person.

 

“Agreement”
has the meaning ascribed to it in the recitals.

 

“Assets and Properties”
of any Person means all assets and properties of every kind, nature, character and description (whether real, personal or mixed,
whether tangible or intangible, and wherever situated), including the goodwill related thereto, operated, owned or leased by such
Person.

 

“Audit Committee”
means the Audit Committee of the Board of Directors of the general partner of IEP, as the same may be constituted from time to
time.

 

“Barberry”
has the meaning ascribed to it in the recitals.

 

“Basket Amount”
means $1,300,000.

 

“Beckton” has
the meaning ascribed to it in the recitals.

 

    	13

    	 

    

 

“Business Day”
means any day of the year other than (i) any Saturday or Sunday or (ii) any other day on which commercial
banks located in New York City are generally closed for business.

 

“Business or Condition”
of any Person means the business, condition (financial or otherwise), properties, assets or results of operations or prospects
of such Person, taken as a whole.

 

“Cap Amount”
shall be equal to $130,786,000.

 

“Closing” has
the meaning ascribed to it in Section 1.4.

 

“Closing Date”
has the meaning ascribed to it in Section 1.4.

 

“Code” means
the Internal Revenue Code of 1986, as amended.

 

“Company” has
the meaning ascribed to it in the recitals.

 

“Contract”
means any contract, lease, commitment, understanding, sales order, purchase order, agreement, indenture, mortgage, note, bond,
right, warrant, instrument, plan, permit or license, whether written or oral, which is intended or purports to be binding and enforceable
and to which CVR, any of its Subsidiaries or the Company is a party.

 

“Contributing Party”
or “Contributing Parties” have the respective meanings ascribed to them in the recitals.

 

“Contribution Shares”
has the meaning ascribed to it in the recitals.

 

“Control” (including
the terms “controlled by” and “under common control with”) means the possession, directly
or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership
of voting securities, by contract or otherwise.

 

“CVR” has the
meaning ascribed to it in the recitals.

 

“CVR Stock”
has the meaning ascribed to it in the recitals.

 

“Dollars” or
numbers proceeded by the symbol “$” means amounts in United States Dollars.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.

 

“Exchange Units”
has the meaning ascribed to it in Section 1.2.

 

    	14

    	 

    

 

“GAAP” means
U.S. generally accepted accounting principles at the time in effect.

 

“Governmental or Regulatory
Authority” means any court, tribunal, arbitrator, authority, administrative or other agency, commission, authority, licensing
board official or other instrumentality of the United States or any state, county, city or other political subdivision thereof,
or of any foreign government having competent jurisdiction over the Business or Condition of any Person.

 

“IEGP” has
the meaning ascribed to it in Section 1.4.

 

“IEP” has the
meaning ascribed to it in the recitals.

 

“IEP Disclosure Schedule”
has the meaning ascribed to it in the introductory paragraph of Article V.

 

“IEP Registration Rights
Agreement” means that certain Registration Rights Agreement dated as of June 30, 2005 by and among American Real Estate
Partners, L.P. (now known as IEP), Highcrest Investors Corp., Arnos Corp., Cyprus, LLC and Gascon Partners, as amended by Amendment
No. 1 thereto, dated as of August 8, 2007.

 

“IEP Registration Rights
Joinder” has the meaning ascribed to it in Section 1.4.

 

“IEP Units”
means the depositary units representing limited partner interests of IEP.

 

“Indemnified Person”
or “Indemnified Persons” have the respective meanings ascribed to them in Section 8.1(a).

 

“Laws” means
all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of the United States or any
state, county, city or other political subdivision or of any Governmental or Regulatory Authority.

 

“License” means
licenses, permits, certificates of authority, authorizations, approvals, registrations, findings of suitability, variances, exemptions,
certificates of occupancy, orders, franchises and similar consents granted or issued by any Governmental or Regulatory Authority.

 

“Lien” means
any mortgage, lien (except for any lien for Taxes not yet due and payable), charge, restriction, pledge, security interest, option,
lease or sublease, claim, right of any third party, easement, encroachment, encumbrance or other adverse claim of any kind or description.

 

    	15

    	 

    

 

“Loss” or “Losses”
means any and all liabilities, losses, costs, claims, obligations, damages (including consequential damages if and to the extent
actually paid to a third party in connection with a Third Party Claim, amounts paid in settlement, and reasonable expenses of investigation,
enforcement and collection), penalties and expenses (including attorneys’ and accountants’ fees and expenses and costs
of investigation and litigation), whether absolute, accrued, conditional or otherwise; provided, however, that the
Losses for which any Indemnified Person shall be entitled to indemnification with respect to any claim hereunder shall be net of
any (i) tax benefit, (ii) insurance proceeds and (iii) other amounts to the extent actually realized or received, as applicable,
at any time and from time to time by such Indemnified Person by reason of or in connection with the same matters, facts or circumstances
giving rise to such claim for indemnification hereunder (including without limitation any future such recoveries).

 

“Material Adverse Effect”
or “Material Adverse Change,” as to any Person, means a material adverse change (or circumstance involving a
prospective change) in the Business or Condition of such Person. Unless the context otherwise indicates or requires, any reference
herein to a “Material Adverse Effect” or “Material Adverse Change” shall mean a “Material Adverse
Effect” or “Material Adverse Change” with respect to CVR its Subsidiaries and the Company, taken as a whole.

 

“Nasdaq” means
the Nasdaq Stock Market.

 

“Order” means
any writ, judgment, decree, injunction or similar order of any Governmental or Regulatory Authority (in each such case whether
preliminary or final).

 

“Person” means
any natural person, corporation, limited liability company, general partnership, limited partnership, proprietorship, other business
organization, trust, union, association or Governmental or Regulatory Authority.

 

“Securities Act”
means the Securities Act of 1933, as amended, including the rules and regulations promulgated thereunder.

 

“SEC” means
the Securities and Exchange Commission.

 

“Subsidiary”
means, with respect to any Person at any date, any corporation, limited or general partnership, limited liability company, trust,
association or other entity (i) the accounts of which would be consolidated with those of such Person in such Person’s
consolidated financial statements if such financial statements were prepared in accordance with GAAP or (ii) of which
more than 50% of (A) the outstanding capital stock having (in the absence of contingencies) ordinary voting power to
elect a majority of the board of directors of such corporation, (B) the interest in the capital or profits of such
partnership or limited liability company or (C) the beneficial interest in such trust or estate is, at the time of
determination, owned or controlled directly or indirectly through one or more intermediaries, by such Person.

 

    	16

    	 

    

 

“Tax” or “Taxes”
means any and all taxes, charges, fees, levies, duties, liabilities, impositions or other assessments, including, without limitation,
income, gross receipts, profits, excise, real or personal property, environmental, recapture, sales, use, value-added, withholding,
social security, retirement, employment, unemployment, occupation, service, license, net worth, payroll, franchise, gains, stamp,
transfer and recording taxes, fees and charges, imposed by a Tax Authority, whether computed on a separate, consolidated, unitary,
combined or any other basis; and such term shall include any interest whether paid or received, fines, penalties or additional
amounts attributable to, or imposed upon, or with respect to, any such taxes, charges, fees, levies, duties, liabilities, impositions
or other assessments.

 

“Tax Authority”
means the U.S. Internal Revenue Service or any other taxing authority (whether domestic or foreign including, without limitation,
any state, county, local or foreign government or any subdivision or taxing agency thereof (including a United States possession)).

 

“Tax Return”
means any report, return, document, declaration or other information or filing required to be supplied to any taxing authority
or jurisdiction (foreign or domestic) with respect to Taxes, including attachments thereto and amendments thereof, and including,
without limitation, information returns, any documents with respect to or accompanying payments of estimated Taxes, or with respect
to or accompanying requests for the extension of time in which to file any such report, return, document, declaration or other
information.

 

“Third Party Claim”
has the meaning ascribed to it in Section 8.3.

 

“Two Times Prime”
means two times the prime rate published by Citibank, N.A.

 

ARTICLE X

 

Miscellaneous

 

Section 10.1      Investigation.
It shall be no defense to an action for breach of this Agreement that IEP or any of its agents have (or have not) made investigations
into the affairs of CVR or the Company or have Knowledge of a misrepresentation or breach of warranty or that CVR or the Company
or any Contributing Party could not have known of the misrepresentation or breach of warranty.

 

    	17

    	 

    

 

Section 10.2      Survival
of Representations and Warranties. The representations and warranties of the parties hereunder shall survive the Closing for
the shorter of (i) a period of six (6) years from the Closing Date or (ii) for so long as any claim
may be made in respect of such matters under any applicable statute of limitations, as it may be extended.

 

Section 10.3      Entire
Agreement. This Agreement, including the schedules and exhibits hereto, which are incorporated herein and made an integrated
part hereof, constitutes the entire agreement between the parties hereto and supersedes any and all prior discussions and agreements
between the parties relating to the subject matter hereof.

 

Section 10.4      Waiver.
Any term or condition of this Agreement may be waived at any time by the party that is entitled to the benefit thereof, but no
such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such
term or condition. No waiver by any party of any term or condition of this Agreement, in any one or more instances, shall be deemed
to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion. All remedies,
either under this Agreement or by Law or otherwise afforded, will be cumulative and not alternative.

 

Section 10.5      Amendment.
This Agreement may be amended, supplemented or modified only by a written instrument duly executed by or on behalf of each party
hereto.

 

Section 10.6      No
Third Party Beneficiary. The terms and provisions of this Agreement are intended solely for the benefit of each party hereto
and their respective successors or permitted assigns, and it is not the intention of the parties to confer third party beneficiary
rights upon any other Person, except that each Indemnified Person shall be a third party beneficiary of Article VIII.

 

Section 10.7      Assignment;
Binding Effect. No party may assign this Agreement or any right, interest or obligation hereunder without the prior written
consent of the other Parties. This Agreement is binding upon, inures to the benefit of and is enforceable by the parties hereto
and their respective successors and assigns.

 

Section 10.8      Headings.
The headings used in this Agreement have been inserted for convenience of reference only and do not define or limit the provisions
hereof.

 

    	18

    	 

    

 

Section 10.9      Invalid
Provisions. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future
Law, and if the rights or obligations of any party hereto under this Agreement will not be materially and adversely affected thereby,
(a) such provision will be fully severable, (b) this Agreement will be construed and enforced as if such
illegal, invalid or unenforceable provision had never comprised a part hereof, and (c) the remaining provisions of
this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision
or by its severance herefrom.

 

Section 10.10    Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without giving
effect to the conflicts of laws principles thereof, except as to matters relating to the internal affairs of the parties, which
shall be governed by the respective law of their organization or incorporation, as the case may be.

 

Section 10.11    Counterparts.
This Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all of which together
will constitute one and the same instrument.

 

Section 10.12    Waiver
of Jury Trial. EACH PARTY HERETO HEREBY WAIVES TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY ANY OF THEM
AGAINST ANY OTHER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS AGREEMENT, OR ANY OTHER AGREEMENTS EXECUTED IN CONNECTION HEREWITH
OR THE ADMINISTRATION THEREOF OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREIN OR THEREIN. No party to this Agreement shall seek
a jury trial in any lawsuit, proceeding, counterclaim, or any other litigation procedure based upon, or arising out of, this Agreement
or any related instruments or the relationship between the parties. No party will seek to consolidate any such action in which
a jury trial has been waived with any other action in which a jury trial cannot be or has not been waived. THE PROVISIONS OF THIS
SECTION HAVE BEEN FULLY DISCUSSED BY THE PARTIES HERETO, AND THESE PROVISIONS SHALL BE SUBJECT TO NO EXCEPTIONS. NO PARTY HAS IN
ANY WAY AGREED WITH OR REPRESENTED TO ANY OTHER PARTY THAT THE PROVISIONS OF THIS SECTION WILL NOT BE FULLY ENFORCED IN ALL INSTANCES.

 

Section 10.13    Consent
to Jurisdiction. Each party irrevocably submits to the exclusive jurisdiction of any New York State Court in the County of
New York or any courts of the United States of America located in the Southern District of New York, and each party hereby agrees
that all suits, actions and proceedings brought by such party hereunder shall be brought in any such court. Each party irrevocably
waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the venue of
any such suit, action or proceeding brought in any such court, any claim that any such suit, action or proceeding brought in such
a court has been brought in an inconvenient forum and the right to object, with respect to any such suit, action or proceeding
brought in any such court, that such court does not have jurisdiction over such party or the other party. In any such suit, action
or proceeding, each party waives, to the fullest extent it may effectively do so, personal service of any summons, complaint or
other process and agrees that the service thereof may be made by any means permitted by Section 10.15 (other than facsimile
transmission). Each party agrees that a final non-appealable judgment in any such suit, action or proceeding brought in such a
court shall be conclusive and binding.

 

    	19

    	 

    

 

Section 10.14    Expenses.
All expenses, costs and fees in connection with the transactions contemplated hereby (including fees and disbursements of counsel,
consultants and accountants) incurred by (a) the Contributing Parties shall be paid and borne exclusively by the Contributing
Parties and (b) IEP shall be paid and borne exclusively by IEP. All transfer, documentary, sales, use, stamp and registration
Taxes imposed with respect to the contribution and exchange of the Contribution Shares shall be borne by the Contributing Parties.

 

Section 10.15    Notices.
All notices, request, demands and other communications hereunder shall be in writing and shall be delivered personally, by certified
or registered mail, return receipt requested, and postage prepaid, by courier, or by facsimile transmission, addressed as follows:

 

If to any Contributing Party:

White Plains Plaza

445 Hamilton Avenue - Suite 1210

White Plains, NY 10601

Attn: Keith Cozza

 

With a copy to:

Icahn Associates Corp.

767 Fifth Avenue

New York, NY 10153

Attn: Jordan Bleznick

 

If to IEP:

c/o Icahn Enterprises L.P.

White Plains Plaza

445 Hamilton Avenue - Suite 1210

White Plains, NY 10601

Attn: SungHwan Cho

 

    	20

    	 

    

 

With a copy to:

Debevoise & Plimpton LLP

919 Third Avenue

New York, NY 10022

Attn: William D. Regner

 

or to such other address as a party may from time to time designate
in writing in accordance with this Section 10.15. Each notice or other communication given to any party hereto in accordance
with the provisions of this Agreement shall be deemed to have been received (a) on the Business Day it is sent, if
sent by personal delivery, (b) the earlier of receipt of three (3) Business Days after having been sent by certified
or registered mail, return receipt requested and postage prepaid, (c) on the Business Day it is sent, if sent by facsimile
transmission and an activity report showing the correct facsimile number of the party on whom notice is served and the correct
number of pages transmitted is obtained by the sender (provided, however, that such notice or other communication
is also sent by some other means permitted by this Section 10.15), or (d) on the first Business Day after sending,
if sent by courier or overnight delivery.

 

Section 10.16    Further
Assurances. Each of the parties hereto covenants and agrees that, from time to time subsequent to Closing, it will, at the
request of the other party, execute and deliver all such documents, including, without limitation, all such additional conveyances,
transfers, consents and other assurances and do all such other acts and things as such other party may from time to time request
be executed or done in order to better evidence, perfect or effect any provision of this Agreement, or of any agreement or other
document executed pursuant to this Agreement, or any of the respective obligations intended to be created hereby or thereby.

 

    	21

    	 

    

 

IN WITNESS WHEREOF, this Agreement has been
duly executed and delivered by the duly authorized officer of each party hereto as of the date first above written.

 

	 	BARBERRY CORP.
	 	 	 
	 	By:	/s/Keith Cozza
	 	 	Name:   Keith Cozza
	 	 	Title:     Secretary; Treasurer
	 	 	 
	 	BECKTON CORP.
	 	 	 
	 	By:	s/Keith Cozza
	 	 	Name:   Keith Cozza
	 	 	Title:     Secretary; Treasurer

 

	 	HIGH RIVER LIMITED PARTNERSHIP
	 	 	 
	 	By:	Hopper Investments LLC, its general
	 	partner
	 	 	 
	 	By:	Barberry Corp., its sole member
	 	 	 
	 	By:	s/Keith Cozza
	 	 	Name:   Keith Cozza
	 	 	Title:     Secretary; Treasurer

 

	 	KOALA HOLDING LP
	 	 	 
	 	By:	Koala Holding GP Corp., its general
	 	partner
	 	 	 
	 	By:	s/Keith Cozza
	 	 	Name:   Keith Cozza
	 	 	Title:     Secretary; Treasurer

 

[Signature Page to the Contribution and
Exchange Agreement]

 

    	 

    	 

    

 

	 	ICAHN ENTERPRISES L.P.
	 	By:	Icahn Enterprises G.P. Inc., its general 

partner
	 	 	 
	 	By:	/s/ SungHwan Cho
	 	 	Name:  SungHwan Cho
	 	 	Title:    Chief Financial Officer

 

[Signature Page to the Contribution and
Exchange Agreement]

 

    	 

    	 

    

 

Schedule 1.1

 

Contribution and Exchange

 

	Contributing Party	 	Percentage of LLC Shares
 Contributed	 	 	Number of Units of IEP
 Units Received	 
	 	 	 	 	 	 	 
	High River Limited Partnership	 	 	3.53	%	 	 	1,812,381	 
	 	 	 	 	 	 	 	 	 
	Koala Holding LP	 	 	2.88	%	 	 	1,475,990	 
	 	 	 	 	 	 	 	 	 
	Total	 	 	6.41	%	 	 	3,288,371

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]